OREXIGEN(TM) Therapeutics Announces Issuance Of Broad Patents Covering Composition Of Its Lead Anti-Obesity Compounds
The new patent complements a previous patent that similarly covers the composition of OREXIGEN's Contrave(TM), also an anti-obesity combination now in an open-label extension of a phase II/III clinical trial. Contrave is a formulation of bupropion and naltrexone, and U.S. Patent No. 5,817,665 covers various combinations of anti-depressants (e.g. bupropion) with opioid antagonists (e.g. naltrexone). This composition patent covers any use of such combinations and is not limited to weight loss. The patent, awarded to Dr. Lee Dante, is also licensed exclusively to OREXIGEN.
In awarding these patents the USPTO recognized combinations of broad categories of existing pharmaceuticals as new, protected entities that act together to produce a novel effect. Additional patent filings from OREXIGEN are pending.
ABOUT OREXIGEN THERAPEUTICS
OREXIGEN(TM) Therapeutics, Inc. is a privately-held clinical-stage neuroscience company in San Diego, California developing novel strategic approaches to the treatment of obesity. OREXIGEN leverages its proprietary science to design and screen drugs and drug combinations that work together in the central nervous system to enhance satiety, diminish appetite, improve energy expenditure and minimize the body's efforts to compensate for weight loss. OREXIGEN has two lead drug candidates in clinical trials, Contrave(TM) (phase II/III) and Excalia(TM) (phase IIb), along with a pipeline of earlier stage drug combinations now being tested. Each is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. By targeting different groups of neurons OREXIGEN is working to develop compounds that each can achieve a different weight loss profile, providing rapid weight loss where required (Excalia(TM)) or emphasizing steady, sustainable weight loss where preferred (Contrave(TM)). Further information about the company can be found at http://www.orexigen.com.
OREXIGEN cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding the scope of patent protection for OREXIGEN's product candidates, the efficacy and safety of OREXIGEN's product candidates and the potential to obtain regulatory approval for, and effectively treat obesity with, any of these product candidates. The inclusion of forward-looking statements should not be regarded as a representation by OREXIGEN that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in OREXIGEN's business, including, without limitation: the scope and validity of patent protection for OREXIGEN's product candidates; the progress and timing of OREXIGEN's clinical trials, and the potential for OREXIGEN's product candidates to receive regulatory approval on a timely basis or at all; the market potential for obesity, and OREXIGEN's ability to compete in the obesity market. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and OREXIGEN undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
OREXIGEN Therapeutics, Inc.
http://www.orexigen.com
View drug information on Naltrexone Hydrochloride Tablets.
OREXIGEN (tm) therapeutics anunþã eliberarea a largã de brevete care acoperã compoziþiei sale de lider de compuºi anti-obezitate - OREXIGEN(TM) Therapeutics Announces Issuance Of Broad Patents Covering Composition Of Its Lead Anti-Obesity Compounds - articole medicale engleza - startsanatate